抑郁症治疗新药伏硫西汀的药理作用与临床评价

Pharmacology and clinical evaluation of vortioxetine:a new drug for the treatment of depression

抑郁症是一种高患病率、高疾病负担、高复发率、高致残率、高自杀率的慢性精神疾病。目前大部分抗抑郁药依赖单一作用模式发挥疗效,抑郁症的治疗仍未满足诸多临床需求。2013年,伏硫西汀(vortioxetine)通过了美国FDA的批准上市,并于2017年11月,通过了原国家食品药品监督管理局批准上市,用于治疗成人抑郁症。临床研究显示,伏硫西汀可全面缓解抑郁症状并促进患者功能恢复。本文就其药理作用、临床评价、安全性及用法用量等进行阐述。

Depression has become a high prevalence, high disease burden, high disability rate and high suicide rate chronic mental disease. At present, most antidepressants take effects through a single mode of action and have not met many clinical needs.Vortioxetine was approved as a drug for once-daily treatment of adults with MDD by FDA in September 2013, and it was approved as a drug for the treatment of depression in adult patients by CFDA in November 2017. In clinical studies, vortioxetine can improve depressive symptoms and functional recovery. The pharmacological actions, clinical evaluation, safety, dosage and administration were reviewed in this paper.